Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis

Wudhikarn, Kitsada; Johnson, Bradley M.; Inwards, David J.; Porrata, Luis F.; Micallef, Ivana N.; Ansell, Stephen M.; Paludo, Jonas; Villasboas, José C.; Johnston, Patrick B.

doi:10.1016/j.jtct.2022.12.011

Cited by 1 publication

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The upper age limit in most studies was 60 or 65 years [44,45], and only a few retrospective series, subgroup post hoc analyses, and data from international registries have described the outcomes of older patients [46][47][48]. In general, ASCT appears to be a feasible option in selected fit older patients ≤75 years of age, but the 1-year non-relapsed mortality in older patients was only 6.0%, suggesting that age should not be the sole factor determining a patient's eligibility for ASCT [49]. Transplant-ineligible but chimeric antigen receptor (CAR) T-eligible older patients could soon become an accurate and relevant population [50].…”

Section: New Novel and Chemotherapy-free Regimensmentioning

confidence: 99%

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Yamasaki

2024

Hematology Reports

View full text Add to dashboard Cite

Most patients with diffuse large B-cell lymphoma (DLBCL) are >65 years of age, with the number of patients expected to increase in the coming years. A comprehensive geriatric assessment that carefully evaluates fitness status and comorbidities is essential for selecting the appropriate treatment intensity. Although generally healthy patients or those <80 years of age may benefit from standard immunochemotherapy, unfit/frail patients or patients >80 years old may require reduced-intensity chemotherapy or less-toxic drugs. Some new drugs are currently being tested as single or combined agents for first-line treatment, aiming to improve the outcomes of conventional chemotherapy. This review systematically collates and discusses the outcomes associated with the use of immunochemotherapy in older patients with DLBCL, as well as considering the impact of full-dose immunochemotherapy on quality of life in older and frail patients, summarizing the rationale for reduced dosing in the older population, and presenting recommendations for selecting patients likely to benefit from reduced dosing. If preliminary efficacy and safety data are confirmed in future clinical trials, non-chemotherapy-based immunotherapy approaches could become an alternative potentially curative option in frail patients and those >80 years of age with DLBCL.

show abstract

Section: New Novel and Chemotherapy-free Regimensmentioning

confidence: 99%

Outcomes of Older Adults with Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Mayo Clinic Cohort Analysis

Cited by 1 publication

References 29 publications

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature

Contact Info

Product

Resources

About